Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck

NCT04129320 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Change in study design

Conditions

Head and Neck Cancer
Squamous Cell Carcinoma of Head and Neck

Interventions

BIOLOGICAL: enoblituzumab
BIOLOGICAL: MGA012
BIOLOGICAL: MGD013

Sponsor

MacroGenics